SalioGen Therapeutics hit by layoffs, as gene-editing biotechs continue to struggle

SalioGen Therapeutics, a company that raised $135 million to develop a new gene-editing technology, has instituted widespread layoffs and is scaling back its ambitions, according to a person familiar with the situation and employee posts on social media.

It is the latest in a series of retrenchments by high-profile gene-editing companies. A spokesperson for SalioGen declined to comment.

Launched in 2021, SalioGen was among a group of new startups developing technology for inserting full-length genes into patients — a feat that can’t readily be accomplished with older approaches based on the gene-editing technology CRISPR.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Californians headed to HBCUs in the South prepare for college under abortion bans

When I’laysia Vital got accepted to Texas Southern University, a historically Black university in Houston, she immediately began daydreaming about the sense of freedom that

August 29, 2023

Amgen sees highest filings and grants during July in Q3 2023

Share this article Amgen has been focused on protecting inventions in European Patent Office (E/P) with 91 publications in Q3 2023 The European Patent Office

November 24, 2023

Here’s Another Racial-Ethnic Disparity in Back Pain Care

Among Medicare beneficiaries with chronic low back pain and opioid use disorder (OUD), white patients were dramatically more likely to have received nonpharmacologic treatments such

September 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.